PYXS Pyxis Oncology2.23-0.67 (-23.1%)
Premarket Decliner
PYXS Pyxis Oncology3.890.000.0%
Premarket:3.27-0.62 (-15.9%)
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Globe NewswireWed, 9-Sep 7:00 AM
PYXS Pyxis Oncology2.61-1.22 (-31.9%)
PYXS Pyxis Oncology2.70+0.47 (+21.1%)
PYXS Pyxis Oncology1.52-1.85 (-54.9%)
PYXS Pyxis Oncology3.37-0.63-15.8%
Premarket:1.99-1.38 (-41.0%)
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Globe NewswireThu, 18-Dec 7:00 AM